Lenvatinib

Catalog Number	ACM417716928-1
CAS Number	417716-92-8
IUPAC Name	4-[3-Chloro-4-(cyclopropylcarbamoylamino)phenoxy]-7-methoxyquinoline-6-carboxamide
Molecular Weight	426.85
Molecular Formula	C21H19ClN4O4
Canonical SMILES	COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl
InChI	InChI=1S/C21H19ClN4O4/c1-29-19-10-17-13(9-14(19)20(23)27)18(6-7-24-17)30-12-4-5-16(15(22)8-12)26-21(28)25-11-2-3-11/h4-11H,2-3H2,1H3,(H2,23,27)(H2,25,26,28)
InChI Key	WOSKHXYHFSIKNG-UHFFFAOYSA-N
Purity	98%+
Storage	Store in dry, low temperature, sealed, 2-8 °C.
Complexity	634
Exact Mass	426.1094828
Heavy Atom Count	30
Monoisotopic Mass	426.1094828
Topological Polar Surface Area	116Ų

Custom Q&A

What is the chemical formula of Lenvatinib?

The chemical formula of Lenvatinib is C21H19ClN4O4.

What is the stability of Lenvatinib when stored as supplied?

Lenvatinib is stable for 1 year from the date of purchase as supplied.

What is the primary use of Lenvatinib in terms of treating thyroid cancer?

Lenvatinib is used for the treatment of thyroid cancer in patients with local recurrence or metastasis.

What is the main mechanism of action of Lenvatinib in inhibiting tumor growth?

Lenvatinib exerts its mechanism of action via inhibition of multiple receptors of tyrosine kinases, including VEGFR, FGFR, and PDGFR, to prevent tumor angiogenesis and cell proliferation.

What are the biological activities of Lenvatinib in terms of inhibiting kinases?

Lenvatinib is a multi-target kinase inhibitor with potent effects on VEGFR2 and VEGFR3, as well as weaker effects on VEGFR1 and other kinases like FGFR1 and PDGFRα.

What are the side effects of Lenvatinib commonly seen in patients treated for thyroid cancer?

The common side effects of Lenvatinib in thyroid cancer patients include tiredness, joint and muscle pain, decreased appetite, weight loss, nausea, mouth sores, and rash.

How does Lenvatinib compare to other drugs in terms of treatment of thyroid cancer?

Lenvatinib is a multi-target kinase inhibitor that can be more effective in treating thyroid cancer compared to other drugs due to its potent inhibition of VEGFR and other tyrosine kinases.

What regulatory approvals has Lenvatinib received for the treatment of thyroid cancer?

Lenvatinib has been approved by the US FDA and the European Medicines Agency for the treatment of thyroid cancer, specifically in patients with radioactive iodine-refractory differentiated thyroid cancer.

What are the in vivo study results of Lenvatinib in terms of tumor growth inhibition?

Orally administered Lenvatinib at specific doses can effectively inhibit tumor growth, induce tumor regression, and reduce microvascular density in in vivo studies.

How is Lenvatinib described in terms of its chemical properties?

Lenvatinib is a white solid that is soluble in DMSO, has a melting point above 216°C, and a molecular weight of 426.85.

※ Please kindly note that our products are for research use only.